At a glance
ClinicalIndex Comparison RecordN/ACompleted· 160 enrolled
Drug / intervention
Trastuzumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Study to Characterize Patients With HER2-positive Metastatic or Locally Advanced Breast Cancer, Treated by Herceptin® as 1st Line-therapy and Without Progression for at Least 3 Years Followed by a 1-year Prospective Study for Patients Still Alive
In Brief
An observational study evaluating Trastuzumab for Breast Cancer. Completed, enrolled 160 participants across 78 sites.
Detailed Summary
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without progression for at least three years. Patients will be followed prospectively for one year.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedNov 2011
Primary CompletionNov 2012
TodayJul 2026
First PostedNov 29, 2011
Enrollment StartMar 28, 2011
Primary CompletionNov 16, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.6 years ago
Interventions
Trastuzumabdrug